DOI: 10.26155 / VET.ZOO.BIO.201905004
UDC 579.841.93
Authors
M. A. YELSHAZLI, D. A. DEVRISHOV, S. N. MARZANOVA
MOSCOW STATE ACADEMY OF VETERINARY MEDICINE AND BIOTECHNOLOGY - MBA NAMED AFTER K. I. SKRYABIN
Yu. M. KHODAROVICH
INSTITUTE OF BIOORGANIC CHEMISTRY NAMED AFTER ACADEMICIANS M. M. SHEMYAKIN AND Yu. A. OVCHINNIKOV OF THE RUSSIAN ACADEMY OF SCIENCES
Abstract
Brucellosis is an endemic bacterial zoonosis that is prevalent throughout the world, especially in developing countries. The control of the epizootic process is difficult due to the use of live vaccines. The development of new forms of the vaccine using modern methods (in particular, DNA vaccines by cloning the immunoactive genes of B. melitensis Rev-1 strain) will significantly improve the epizootic situation and the safety of immunoprophylaxis. Outer membrane surface protein 31 (Omp31), which is an immunodominant and protective antigen, sp41 protein, which is coupled with bacterial adhesion, and the periplasmic binding protein p39, as a T-cell immunodominant antigen, were used as vaccine antigens. The sequences encoding these proteins were obtained by PCR amplification from the genomic DNA of the vaccine strain B.melitensis Rev-1. These sequences were cloned into the pEGFP-N1 vector. As a result, plasmids for the expression of Brucella antigens in eukaryotic cells were obtained. The accuracy of plasmid assembly and the absence of mutations in amplified sequences was confirmed by PCR and partial plasmid sequencing.
Keywords
B. melitensis, gene, plasmid, vaccine, vector.
